Related Experiment Video
Updated: Aug 7, 2026
Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
Immunoinformatics-aided rational design of multiepitope-based peptide vaccine (MEBV) targeting human parainfluenza
Md Sakib Hossen1,2, Md Nazmul Hasan3,4, Munima Haque5
1Department of Biochemistry and Molecular Biology, Primeasia University, Banani, Dhaka, 1213, Bangladesh. sakib.hossen@primeasia.edu.bd.
Background:
Human parainfluenza viruses (HPIVs) are common RNA viruses responsible for respiratory tract infections. Human parainfluenza virus 3 (HPIV-3) is particularly pathogenic, causing severe illnesses with no effective vaccine or therapy available.
Results:
The current study employed a systematic immunoinformatic/reverse vaccinology approach to design a multiple epitope-based peptide vaccine against HPIV-3 by analyzing the virus proteome. On the basis of a number of therapeutic features, all three stable and antigenic proteins with greater immunological relevance, namely matrix protein, hemagglutinin neuraminidase, and RNA-directed RNA polymerase L, were chosen for predicting and screening suitable T-cell and B-cell epitopes. All of our desired epitopes exhibited no homology with human proteins, greater population coverage (99.26%), and high conservancy among reported HPIV-3 isolates worldwide. All of the T- and B-cell epitopes are then joined by putative ligands, yielding a 478-amino acid-long final construct. Upon computational refinement, validation, and thorough screening, several programs rated our peptide vaccine as biophysically stable, antigenic, allergenic, and non-toxic in humans. The vaccine protein demonstrated sufficiently stable interaction as well as binding affinity with innate immune receptors TLR3, TLR4, and TLR8. Furthermore, codon optimization and virtual cloning of the vaccine sequence in a pET32a ( +) vector showed that it can be readily expressed in the bacterial system.
Conclusion:
The in silico designed HPIV-3 vaccine demonstrated potential in evoking an effective immune response. This study paves the way for further preclinical and clinical evaluation of the vaccine, offering hope for a future solution to combat HPIV-3 infections.
Insights
A novel peptide vaccine against Human parainfluenza virus 3 (HPIV-3) was designed using immunoinformatics. This computational approach shows promise for developing effective HPIV-3 vaccines and treatments.
Area of Science:
- Virology
- Immunology
- Vaccine Design
Background:
- Human parainfluenza viruses (HPIVs) cause respiratory infections.
- Human parainfluenza virus 3 (HPIV-3) is a particularly severe pathogen.
- No effective vaccine or therapy currently exists for HPIV-3.
Purpose of the Study:
- To design a multi-epitope peptide vaccine against HPIV-3.
- To utilize a reverse vaccinology approach for vaccine development.
- To identify and screen T-cell and B-cell epitopes from HPIV-3 proteins.
Main Methods:
- Systematic immunoinformatic analysis of the HPIV-3 proteome.
- Selection of matrix protein, hemagglutinin neuraminidase, and RNA-directed RNA polymerase L.
- Prediction and screening of T-cell and B-cell epitopes with high population coverage and conservancy.
- Computational refinement, validation, and stability assessment of the final peptide construct.
Main Results:
- Identified epitopes showed no homology with human proteins and 99.26% population coverage.
- The designed vaccine construct is biophysically stable, antigenic, non-toxic, and non-allergenic.
- The vaccine demonstrated stable binding affinity with innate immune receptors TLR3, TLR4, and TLR8.
- Codon optimization and virtual cloning confirmed feasibility for bacterial expression.
Conclusions:
- The in silico designed HPIV-3 vaccine shows potential for eliciting a robust immune response.
- This study provides a foundation for further preclinical and clinical evaluations.
- The developed vaccine offers a potential future solution for combating HPIV-3 infections.
